Select late-stage CMC, non-clinical studies, and quality programs to accelerate NRS-033 towards pivotal studies and registration in opioid use disorder
Active Cooperative Agreement Awarded Last action
- Award ID
- U01DA061643
- Recipient
-
Nirsum Laboratories, Inc. UEI JQEHSCRCNRT5
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $29,198,325
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 78% complete
- Place of performance
- New York, NY 10281, USA
Award details come from USAspending.gov.
Description
- Abstract
- The epidemic of opioid use disorder (OUD) is the greatest public health crisis the united states has faced in a generation. Yet essentially the same three food and drug administration (FDA) approved medications for OUD (moud), in various formulations, have been available since the crisis began decades ago: opioid agonist methadone, partial agonist buprenorphine and antagonist naltrexone. These few legacy defenses against the staggering tide of addiction have proven feeble, primarily due to short treatment retention and lack of access. These moud are poorly accepted, offered to 400% longer duration of action than XR-NTX, corresponding to dramatically improved treatment retention. Given its gradual decline and high trough levels of plasma nalmefene, NRS-033 should provide stronger and more consistent opioid blockade, as well as a more forgiving dosing schedule than XR-NTX. Such upgrades are critical for socially complex patients in today's illicit market dominated by potent synthetic opioids, different from that decades ago. Also, NRS-033 is a room temperature stable ready-to-use prefilled syringe, much easier to use and clinically accessible than XR-NTX. Our proposed aims seek to expedite NRS-033 into phase 3 trials and FDA registration, hence include: late stage (registration batch) chemistry, manufacturing, and controls (CMC) for API and drug product, registration enabling non-clinical studies, quality systems, and regulatory engagement with FDA. Despite significantly DE-risked development, the timely advance of NRS-033 will have a profound public health impact once available, reducing relapse and overdose risk for abstinence-seeking OUD patients, helping defeat the prevailing stigma that opioid dependence is inescapable.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $4,947,774 | |
| Amendment | $4,947,774 | |
| Amendment | $4,947,774 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $4,785,001 | |
| Amendment | $4,785,001 | |
| Original award | $4,785,001 |
Show all 11
Quick answers
Who received award U01DA061643?
U01DA061643 was awarded to Nirsum Laboratories, Inc. by National Institute on Drug Abuse (National Institutes of Health) on August 1, 2024.
How much is award U01DA061643 worth?
$29,198,325 has been obligated on U01DA061643.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award